Search results
23 gru 2022 · Conclusions: The immunization effect of COVID-19 vaccine in the elderly is obvious, especially after multiple vaccinations, and the incidence of AEs in the elderly is low, which proves that the vaccination of the elderly is safe and effective.
Phase II trials for many vaccines show good antibody responses. Unpublished Phase III analyses suggest high efficacy. As the world prepares for a mass roll-out of newly approved coronavirus disease 2019 (COVID-19) vaccines, older people with frailty are taking centre stage.
These results indicate that CoronaVac has a good safety profile in the older population, which might help to alleviate vaccine hesitancy due to concerns of adverse events associated with COVID-19 vaccines.
21 lut 2022 · The prioritisation of recommended vaccinations among frail, older people should aim to help identify new approaches for promoting the health of this population and support efforts that contribute to healthy ageing.
8 kwi 2021 · Recently published trial results show remarkable COVID-19 vaccine efficacy. However, it remains possible that, despite being protective among adults up to age 75, the efficacy of a COVID-19 vaccine among the elderly will be substantially lower.
21 mar 2022 · This study assessed the CoronaVac vaccine in people aged 60 years or older, and showed effectiveness of 86·3% (95% CI 84·5–87·9) for the prevention of COVID-19-related hospitalisation and 86·5% (84·6–88·1) for the prevention of COVID-19-related deaths among people who were fully vaccinated (ie, (≥14 days after receipt of the second ...
4 lut 2021 · Older people are vulnerable to SARS-CoV-2 infections and complications; thus, they are a priority group to receive COVID-19 vaccines. This review discusses considerations for COVID-19 vaccines for older adults.
